According to Mark Barfoot, Managing Director at Hyphen, employing both Stratasys FDM and PolyJet 3D printing technologies has enabled the product development team to focus on ensuring customers get the perfect design before the final mold is produced.

"The main benefit for Hyphen is that when we go to market, the product is manufactured right the first time, ensuring our customers get something that has been optimised specifically for them. We've seen a real mind-set change in our engineers. They are no longer willing to live with one prototype and hope it works, but instead are now iterating daily to ensure they get the optimum design."

With an in-house environmental testing facility, Hyphen puts its 3D printed prototypes through the paces including testing with extreme heat and vibration, enabling the identification of potential field failures or other issues early in the product development cycle.

"The Stratasys FDM process creates functional prototypes that have high heat deflection temperatures and exceptional chemical and solvent resistance, which is essential for us, as some projectors need products that must withstand very high temperatures," commented Barfoot. "The materials are an exact match of the final product, so whether we are doing vibration or drop-testing, EMI, or thermal, they will behave very similar to the final injection molded parts."

For more rubber-like materials, the company turned to Stratasys' PolyJet-based Connex multi-material 3D printing technology, which enables Hyphen to combine rigid and flexible material properties.

"We are seeing more and more companies combining PolyJet and FDM 3D printed parts in the same products - enabling true functional realism during the design phase," said Bruce Bradshw, Director of Marketing, Stratasys. "By producing working prototypes that can be tested in extreme conditons, manufacturers can more easily evaluate product features and continue to make iterative changes until the optimal design is achieved."

For the medical sector, Hyphen used both FDM and PolyJet 3D printing technologies to develop a prototype for the VeinViewer® product, an innovative device that utilizes near-infrared light to detect subcutaneous blood and instantly projects a real-time image of the patient's veins directly onto the surface of the skin. The VeinViewer imaging system is designed to help improve peripheral vascular access and is currently being used in facilities in over 40 countries around the world.

"Having the ability to introduce both technologies into the additive manufacturing process was critical to perfecting the design and functionality of this product," says Barfoot. "Using the PolyJet system allowed us to trial the product using rubber overmolding and achieve a smooth surface finish, which gave us an accurate prototype to test with nurses early on in the process. With the FDM technology we were able to build functional parts, allowing us to conduct drop tests well before we got to tooling."

Watch the video to see how Hyphen is optimizing its product design with Stratasys

Hyphen is a full-service, rapid prototyping and environmental testing center with Canada's widest range of capabilities under one roof. Hyphen's rapid prototyping and 3D printing technologies offer access to all the latest technologies and materials for developing prototypes. Engineers, technicians and technologists use Hyphen's environmental testing to identify potential field failures and testing issues early in the product development cycle, and mitigate risks. Our fully-equipped facility can simulate a variety of mechanical and electrical tests. As a division of Christie Digital Systems Canada Inc., Hyphen is able to extend a long history of expertise to our customers. The Hyphen team of professionals have firsthand experience in shortening lead times and project-design cycles. For more information on Hyphen, visit http://www.hyphenservices.com.

About Christie Medical Holdings, Inc.

Christie Medical Holdings Inc. is a global company based in Memphis, Tenn., that discovers, develops and commercializes medical technologies. The company's market-leading product, VeinViewer®, is a mobile vascular imaging system that allows health care providers to clearly see accessible vasculature as a real time HD image, directly on the surface of the skin. Christie Medical Holdings Inc. is owned by Christie Digital Systems Inc., a global visual technologies company and a subsidiary of Ushio Inc., Japan (JP:6925). For more information on Christie Digital Systems or Christie Medical Holdings, visit http://www.christiedigital.com.

About Stratasys Ltd.

Stratasys Ltd. (Nasdaq: SSYS), headquartered in Minneapolis, Minn. and Rehovot, Israel, manufactures 3D printers and materials for prototyping and production. The company's patented FDM® and PolyJet® processes produce prototypes and manufactured goods directly from 3D CAD files or other 3D content. Systems include 3D printers for idea development, prototyping and direct digital manufacturing. Stratasys subsidiaries include MakerBot and Solidscape, and the company operates the RedEye digital-manufacturing service. Stratasys has more than 1500 employees, holds over 500 granted or pending additive manufacturing patents globally, and has received more than 20 awards for its technology and leadership. Online at: http://www.stratasys.com or http://blog.stratasys.com.

Stratasys, FDM, and RedEye are registered trademarks, and PolyJet and Connex are trademarks of Stratasys Ltd. and or its subsidiaries or affiliates.

Certain information included or incorporated by reference in this press may be deemed to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "project" or other similar words, but are not the only way these statements are identified. These forward-looking statements may include, but are not limited to, statements relating to the company's objectives, plans and strategies, statements regarding the company's products and their expected performance, statements that contain projections of results of operations or of financial condition (including, with respect to the MakerBot merger) and all statements (other than statements of historical facts) that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. The company has based these forward-looking statements on assumptions and assessments made by its management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among other things: the company's ability to efficiently and successfully integrate the operations of Stratasys, Inc. and Objet Ltd. after their merger as well as the ability to successfully integrate MakerBot into Stratasys; the overall global economic environment; the impact of competition and new technologies; general market, political and economic conditions in the countries in which the company operates; projected capital expenditures and liquidity; changes in the company's strategy; government regulations and approvals; changes in customers' budgeting priorities; litigation and regulatory proceedings; and those factors referred to under "Risk Factors", "Information on the Company", "Operating and Financial Review and Prospects", and generally in the company's annual report on Form 20-F for the year ended December 31, 2012 filed with the U.S. Securities and Exchange Commission and in other reports that the Company has filed with the SEC. Readers are urged to carefully review and consider the various disclosures made in the company's SEC reports, which are designed to advise interested parties of the risks and factors that may affect its business, financial condition, results of operations and prospects. Any forward-looking statements in this press release are made as of the date hereof, and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

(Date:9/25/2017)... , Sept. 25, 2017 EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...

(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board ... Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will ... Dr. Puffer’s retirement at the end of 2018. Upon assuming the role of President ...

(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...

(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...